A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
European Journal of Cancer2016Vol. 69, pp. 158–165
Citations Over TimeTop 10% of 2016 papers
Laura D. Locati, Federica Perrone, Barbara Cortelazzi, Cristiana Bergamini, Paolo Bossi, Enrico Civelli, Carlo Morosi, Salvatore Lo Vullo, Martina Imbimbo, Pasquale Quattrone, Gian Paolo Dagrada, Roberta Granata, Carlo Resteghini, Aurora Mirabile, Salvatore Alfieri, Ester Orlandi, Luigi Mariani, G. Saibene, S. Pilotti, Lisa Licitra
Related Papers
- → Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).(2021)76 cited
- → Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer(2007)26 cited
- → Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial(2023)14 cited
- → 265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial(2020)10 cited
- → FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.(2018)4 cited